Babies and young children treated with the anti-HIV drug dolutegravir, in combination with other anti-HIV drugs, are more likely to keep the virus under control, compared to those treated with standard anti-HIV treatment combinations. This is according to results from...

A once-a-day antiretroviral medicine that is low-cost and easy for children to take is also more effective at suppressing HIV than standard treatments, according to a global trial led by researchers at UCL.

It was announced at the 8th European AIDS Conference that the laureates of the Hector Research Award in HIV 2021 in clinical and/or epidemiological science was received Angela Colbers and David Burger on behalf of the ODYSSEY trial team! The winning paper Simplified...

March 2021

The anti-HIV drug Dolutegravir improves outcomes for children with HIV infection when given in a 3-drug anti-HIV combination. These results come from the ODYSSEY trial which was presented at the Conference

UNIVERSAL, the newly funded European-African clinical research partnership will develop, evaluate and register two new antiretroviral formulations for infants and children newly diagnosed with HIV initiating antiretroviral therapy, and for children failing...